Prognostic Value of Serum β2-Microglobulin Level in Patients with Non-Hodgkin′s Lymphoma
10.3321/j.issn:1000-467X.2001.04.015
- VernacularTitle:非霍奇金氏淋巴瘤患者血清β2-微球蛋白检测对预后的价值
- Author:
Zhong-Jun XIA
1
;
Ren-Wei HUANG
;
Xiang-Yuan WU
;
Gui-Zhen LIN
;
Li ZHANG
;
Zhong-Zhen GUAN
Author Information
1. the Third Affiliated Hospital Sun Yat-sen University of Medical Sciences
- From:Chinese Journal of Cancer
2001;20(4):406-408
- CountryChina
- Language:Chinese
-
Abstract:
Objective: This study was designed to investigate the prognostic value of serum β2-micorglobulin(β2-MG) level in non-Hodgkin s lymphoma(NHL) patients and its correlation with Ann Arber staging system and the pathological type. Method: Serum β2-MG levels in 75 de novo NHL patients were measured by radioimmunoassay. Results: The β2-MG level in 75 NHL patients was higher than that in nomal control level in 52％ of the patients and correlated with the Ann Arber stage. There was significant difference between two groups (P<0.01). The international prognostic index (IPI) and the response rate to chemotherapy were also correlated with the β2-MG level in serum. The response rate, the complete response, and partial response were 87.2%, 61.5%, and 25.6% in normal serum β2-MG group, while in the high β2-MG group they were only 75.0%, 50.0%, and 25.0%, respectively, which were significantly different between the two groups (P<0.05). The difference of 5-year survival between the two groups was significant (64.1% vs 27.8%, P<0.05) and favorable in normal β2-MG group. Conclusion: β2-MG level in serum is an independen prognostic factor in de novo NHL, and the patients with abnormal β2-MG level in serum have a unfavorable prognosis.
